This cross-sectional study investigated the effect of early highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV) type 1-specific CD8 T cell responses in children. HIV-1-specific CD8 T cell responses were quantified using an enzyme-linked immunospot assay to measure interferon-g-secreting cells. HIV-1-infected children were classified by time of HAART initiation prior to age 1 year or after age 2 years as early ( ) n = 24 or late ( ) treated. The magnitude and breadth of the HIV-1-specific CD8 T cell response n = 28 was significantly lower in children receiving early compared with late HAART treatment ( and .0001, respectively). However, total CD8 T cell responses in the early HAART P = .0007 treatment group did not differ significantly from those of age-matched non-HAART-treated controls ( ). Thus, the reduced magnitude and breadth of the HIV-1-specific CD8 T cell n = 30 response in early HAART-treated children is due to their younger age.
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In adults, human immunodeficiency virus (HIV) type 1 replication rapidly increases during acute infection but is usually controlled within 3-4 months, resulting in lower levels of plasma viremia and resolution of clinical symptoms. Equilibrium between the rate of HIV-1 replication and the host's immune response yields a "virologic set point," which can be predictive of the time course of disease progression [1] [2] [3] . In neonates, HIV-1 plasma viremia peaks at significantly higher levels than in adults and stabilizes at about age 2 months, after which it remains largely constant, without showing the marked inflection point at 3-4 months seen in adults. The subsequent risk of immunologic failure and clinical disease progression increases 4-fold for each 1-log rise in virus load during the first year of life. This delay in reaching a virologic set point in the majority of HIV-1-infected infants [4] [5] [6] [7] has been attributed to the immaturity of the neonatal immune response [8] , which is characterized by both a higher number and turnover of CD4 T lymphocytes.
There is substantial evidence supporting a role for HIV-1-specific cellular immune responses in the containment of primary viremia in adults [9] [10] [11] , but studies in neonates and children have been limited [12] [13] [14] [15] [16] [17] . Although the breadth and magnitude of the HIV-1-specific CD8 T cell responses in older children is equivalent to that observed in adults [17] , detection of virus-specific cellular immune responses during infancy and early childhood is controversial [13, 14] .
The introduction of highly active antiretroviral therapy (HAART) has led to a dramatic decrease in mortality and morbidity in HIV-infected adults in the United States [18] . There is accumulating evidence that early intervention with HAART during primary HIV-1 infection may preserve immunologic function [19] . However, effective suppression of plasma viremia in response to HAART may adversely impact the development of antigen-driven HIV-1-specific CD8 T cell responses [20] [21] [22] [23] [24] . This effect may be considered deleterious in cases where active HIV-1 replication resumes because of drug resistance or a break in the dosing regimen.
Within the last 3 years, protocols for the early initiation of HIV-1 drug therapy in vertically infected infants have been introduced. These include combination regimens of nucleoside analogues with different protease inhibitors, such as the combination of zidovudine, lamivudine (3TC), and ritonavir (AIDS Clinical Trial Group [ACTG] Protocol 345) or stavudine, 3TC, and nevirapine, with or without the addition of nelfinavir (ACTG Protocol 356). In a preliminary report on the HIV-1-specific immune responses in 2 early HAART-treated infants with effective control of viremia, antibody production and HIV-1-specific cytotoxic T lymphocytes were undetectable at early time points evaluated soon after the initiation of therapy [25] . In the current study, we investigated, in a large, cross-sectional analysis of infected infants and children, whether early initiation of HAART effects the quality (breadth) and/or the quantity (frequency) of HIV-1-specific cytotoxic T cell responses later in life. The results shed light on whether early initiation of HAART in vertically infected infants suppresses the subsequent development of HIV-1-specific CD8 T cell responses by removing the antigenic stimulus required for maintenance of effector CD8 T cells and maturation of HIV-1-specific memory CD8 T cells or, alternatively, whether early HAART treatment might help preserve HIV-1-specific CD4 T cells, which could support the development of HIV-1-specific CD8 T cell responses.
Materials and Methods
Patients. Patients were treated and followed at clinical sites in New York City: the Pediatric AIDS Program, New York University/Bellevue Hospital; Pediatric Infectious Diseases Division, Albert Einstein College of Medicine, Jacobi Hospital; and Pediatric Infectious Diseases, Saint Vincent's Hospital. All subjects acquired HIV-1 infection through vertical transmission and were diagnosed on the basis of у2 positive viral cultures and 1 positive HIV-1 polymerase chain reaction (PCR). The children were enrolled in combination antiretroviral treatment protocols as they became available. All patients were treated with HAART (2 nucleoside reverse transcriptase inhibitors [NRTIs] and either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor). Racially, the children were black, white, and Hispanic. Ages at initiation of HAART were 0.1-13.1 years. HIV-1-infected infants and children were stratified into 2 groups on the basis of their age at initiation of HAART (table 1). In the early treatment group (n = ), HAART was initiated at !1 year of life, whereas HAART was 24 initiated in the later treatment group ( ) at у2 years of life. n = 28 HIV-1-specific CD8 T cell responses were quantified in this crosssectional study 1.2 years, on average, after the initiation of HAART. Patients were then further stratified on the basis of virus loads at the time of sampling as either virologically suppressed (virus load, !400 copies/mL), virologic responders (у1.0 log decrease in virus load after initiation of therapy), or virologic nonresponders (!1.0 log decrease in virus load after initiation). In the early HAART treatment group, 10 children were virologically suppressed, 8 were virologic responders, and 6 were virologic nonresponders. Among the late HAART-treated children, 9 were virologically suppressed, 10 were virologic responders, and 9 were virologic nonresponders. To control for the effect of age on the HIV-1-specific CD8 T cell response, a control group of 30 HIV-1-infected children was included who, at the time of sample, either had received no antiretroviral therapy or were on regimens containing only NRTIs. The mean age for early and late HAARTtreated children was 1 Measurement of plasma HIV-1 RNA load. HIV-1 RNA copy numbers in plasma were determined by reverse transcriptase-PCR (Roche, Nutley, NJ) in accordance with the manufacturer's instructions, with a lower limit of detection of 400 HIV-1 RNA copies/mL.
Isolation of peripheral blood mononuclear cells (PBMC)
. Fresh blood (3-6 mL) was collected in EDTA anticoagulant. PBMC were then isolated by ficoll-hypaque centrifugation and cryopreserved in medium containing 90% fetal calf serum (FCS) and 10% dimethyl sulfoxide.
Recombinant vaccinia vectors. Recombinant vaccinia vectors expressing HIV-1 antigens (HIV-1 IIIBenv-gp160, IIIBgag-p55, IIIBnef, and IIIBpol) were used in ELISA-linked immunospot (ELISPOT) assays. Vaccinia strain TK Ϫ was used as a control (Therion, Cambridge, MA).
ELISPOT assay. To detect interferon (IFN)-g release from HIV-1 antigen-specific T cells, an ELISPOT assay was used based on a method published elsewhere [26] with some modification. In brief, 96-well multiscreen plates (Millititer MAHAS 4510; Millipore, Bedford, MA) were coated overnight at 4ЊC with 5 mg/mL of a primary anti-IFN-g monoclonal antibody (MAb; Mabtech, Stockholm. The antibody-coated plates were then washed 4 times with PBS and blocked for 1 h at 37ЊC with RPMI containing 5% pooled human serum. Cells were washed twice in media, counted, and resuspended in 1% pooled human serum/RPMI. Cells were added in 100 mL of culture medium at 0.5-2.5 ϫ 10 5 per well in duplicates. Recombinant vaccinia virus expressing Env, Gag, Pol, and Nef was added directly to each well at an MOI of 2. One hour after infection, 50 mL of FCS was added and plates were incubated at 37ЊC for 14-20 h. Plates were washed 4 times with PBS containing 0.05% Tween 20, followed by a 2-h incubation with 50 mL of the secondary antibody (1 mg/mL, biotin-conjugated anti-IFNg MAb; Mabtech). Plates were washed again 4 times in PBS containing 0.1% Tween 20 and incubated for 1 h at room temperature with avidin-bound horseradish peroxidase H (Vectastain Elite kit; Vector Laboratories, Burlingame, CA). The plates were then washed 3 more times, then incubated for 5-min in stable diaminobenzidine (Research Genetics, Huntsville, AL). After the incubation, the plates were rinsed with tap water and allowed to dry completely. Spots were counted with a stereo microscope (Stemi 2000; Carl Zeiss, New York) at ϫ20-40 magnification.
The raw counts from the ELISPOT were normalized to a quantity of spot-forming cells (SFC) per 10 6 PBMC. The sum of the individual responses to Env, Gag, Pol, and Nef was termed the patient's total CD8 T cell response. The number of SFC from each vaccinia control well (!25 SFC) was subtracted as background; responses 115 SFC/10 6 PBMC were considered significant. On the basis of results in previous studies in adolescents and adults that used the same ELISPOT method [26] [27] [28] , the strength of the total CD8 T cell response (SFC/10 6 PBMC) was considered "weak" (15-200), "moderate" (201-500), or "strong" (1500). The response was defined as broad when 3 or 4 of the HIV-1 antigens (Env, Gag, Pol, and Nef) were recognized.
Statistical methods. Descriptive statistics, correlations, and statistical tests for analysis of significance of differences between groups, based on data type and distribution (Spearman's rank order correlations, Mann-Whitney rank sum test, and Kruskal-Wallis one-way analysis of variance [ANOVA] on ranks), were performed using the SigmaStat 5.0 statistical software package (SPSS, Chicago). NOTE. Patients E01S-E10S and L01S-L09S were virologically suppressed (S), E11R-E18R and L10R-L19R were virologic responders (R), and E19N-E24N and L20N-L28N were virologic nonresponders (N). Virus load was measured by Roche reverse transcriptase-polymerase chain reaction and is reported in copies (cps)/mL.
Results

Analysis of HIV-1-specific CD8 T cell response in early versus
late HAART-treated children. HIV-1-specific CD8 T cell responses were quantified by use of a sensitive recombinant vaccinia-based IFN-g ELISPOT assay [26] . This assay was used elsewhere successfully to measure the frequency of HIV-1-specific CD8 T cell responses in 2 HIV-1-infected children [17] . Of importance, in earlier depletion experiments, the IFN-g-producing cells detected by this assay were shown to be antigen-specific CD8 T cell effectors [26] . Moreover, results with the ELISPOT assay have correlated with other assays for quantification of HIV-1-specific cytotoxic T cell (CTL) responses, including tetramer staining and limiting dilution assays [26, 29] . Thus, ELISPOT assays were used to quantify the HIV-1-specific CD8 T cell response against individual HIV-1 antigens (figure 1) and to determine the total CD8 T cell response (figure 2).
In patients receiving early treatment with HAART, the mean total CD8 T cell response for Env, Gag, Pol, and Nef antigens was 67 ‫ע‬ 92 SFC/10 6 PBMC. The degree of CD8 T cell activity as measured by the ELISPOT assay was dependent on the level of viral suppression, since nonresponders mounted the strongest response (mean, SFC/10 6 PBMC). In comparison, the 113 ‫ע‬ 91 HIV-1-specific CD8 T cell response in children receiving early treatment with HAART and virologic suppression was significantly weaker (mean, SFC/10 6 PBMC; ; figure 32 ‫ע‬ 53 P = .03 3A). In patients receiving HAART later, the mean overall HIV-1-specific CD8 T cell response was SFC/10 6 PBMC. 522 ‫ע‬ 789 Children with virologic suppression within the late treatment group again had the weakest overall HIV-1-specific CD8 T cell response (mean, SFC/10 6 PBMC). Responders had 319 ‫ע‬ 344 a stronger response (mean, SFC/10 6 PBMC), while 344 ‫ע‬ 384 nonresponders had the strongest response (mean, 922 ‫ע‬ 1245 SFC/10 6 PBMC). However, these difference in HIV-1-specific CD8 T cell responses within the late treatment group for children with distinct patterns of virologic response to HAART did not reach statistical significance ( ). When the median P = .1 CD8 T cell responses directed at individual HIV-1 antigens were compared in the early and late HAART treatment groups, HIV-1 Env-and Nef-directed CD8 T cell responses were significantly stronger in the late than in the early treatment group (P = and .013, respectively). .01
Comparison of total HIV-1-specific CD8 T cell responses of HAART and non-HAART-treated children. On the basis of data distribution, a nonparametric Kruskal-Wallis ANOVA on ranks test was used to compare the groups of children with early , Kruskal-Wallis analysis of P = .0001 variance on ranks). To isolate group(s) that differed from others, an all-pairwise multiple-comparison procedure for unequal treatment group sizes (Dunn's method) was used. Although the late HAARTtreated patient group was significantly different from both early HAART-treated and non-HAART-treated age-matched control groups ( ), there was no difference between early HAART-treated and P ! .05 control groups. and late initiation of HAART and the control group treated with non-HAART antiretroviral therapy. There was a statistically significant difference between these 3 groups ( ; figure 3B) . P = .0007 Multiple pairwise comparison (Dunn's method) showed a significant difference in the median total HIV-1-specific CD8 T cell responses between the group of children with late initiation of HAART and the control group ( ), whereas no difference P ! .05 was found between the median total HIV-1-specific CD8 T cell responses of the early HAART-treated group and the agematched non-HAART-treated control group. When the median total individual HIV-1 Env-, Gag-, Pol-, and Nef-specific CD8 T cell responses were analyzed among early HAART, late HAART, and non-HAART-treated patients, statistically significant differences were found between the groups for HIV-1 Env-, Pol-, and Nef-directed responses (one-way ANOVA on ranks,
, .001, and .0002, respectively). A multiple pair-P = .002 wise comparison consistently revealed that the HIV-1 antigenspecific CD8 T cell responses in the late HAART treatment group were significantly stronger than the corresponding CD8 T cell responses in both the early HAART and the non-HAART treatment groups (Dunn's method, ).
The breadth of HIV-1-specific CD8 T cell response in HAART and non-HAART-treated children. For children with late initiation of HAART, unlike the age-matched control group of non-HAART-treated children, HIV-1-specific CD8 T cell responses were directed against a wider range of HIV-1 antigens ( ). When compared with early HAART-treated chil-P = .0034 dren, there was a trend toward greater breadth for the later HAART-treated children, which became statistically significant for HIV-1 antigen-specific CD8 T cell responses у100 SFC/10 6 PBMC ( and .00012 for responses у200 SFC/10 6 P = .00018 PBMC). There was no statistically significant difference in the breadth of HIV-1-specific CD8 T cell responses of any magnitude between the early HAART-treated and the non-HAART-treated age-matched control group ( figure 4) .
HIV-1-specific CD8 T cell responses in the age-matched control group. For children in the non-HAART-treated control group, the mean total HIV-1-specific CD8 T cell response was SFC/10 6 PBMC (range, 0-577). Mean CD8 T cell 63 ‫ע‬ 126 responses against individual HIV-1 antigens were , 25 ‫ע‬ 61 , , and 3 SFC/10 6 PBMC for HIV-1 Env-, 23 ‫ע‬ 56 7 ‫ע‬ 30 7 ‫ע‬ 2 Gag-, Pol-, and Nef-specific CD8 T cells, respectively.
Discussion
For children, as for adults, there is a strong association between disease progression and baseline HIV-1 plasma RNA levels across a wide range of ages [4, 5, 30] . With the rate of disease progression often determined during primary infection, early initiation of HAART is the most promising approach for effectively decreasing virus burden and possibly altering the natural history of HIV-1 infection in infants and children. Within the last 3 years, protocols for early initiation of HAART in HIV-1-infected infants have been introduced. With these regimens, reductions in virus load have been observed in infants !3 months old at levels comparable to those achieved in adults [31] .
In this study, we investigated the effect of early treatment with HAART on the development of HIV-1-specific CD8 T cell responses in children to determine what influence HIV-1 load reduction during infancy has on both the strength and breadth of the HIV-1-specific effector CD8 T cell response as measured by IFN-g ELISPOT. Our results provide evidence that an HIV-1-specific CD8 T cell response is possible in children receiving early treatment with HAART, even in the absence of a detectable plasma virus load. Because of the recent development of early HAART treatment protocols for infants, patients in our early treatment group are now younger than the HIV-1-infected children for whom HAART was initiated when it first became available. For the non-HAART-treated children in the control group, a strong positive correlation was found between the total HIV-1-specific CD8 T cell response, the HIV-1 Gag-, Pol-, and Nefspecific CD8 T cell responses, and the age of the child at the time CD8 T cell responses were analyzed. The median total HIV-1-specific CD8 T cell responses for the non-HAART-treated control group (mean age at time of ELISPOT assay, 1.71 years) did not differ significantly from the early HAART treatment group (mean age at time of ELISPOT assay, 1.76 years). How-ever, the median total HIV-1-specific CD8 T cell responses did differ significantly from the late HAART-treated children (mean age at time of ELISPOT assay, 8.1 years). Although the longterm effects of the early initiation of HAART on the strength and breadth of the HIV-1-specific CD8 T cell response are not known, especially in children with complete virologic suppression, there is evidence that the observed difference between the 2 HAART treatment groups was predominantly influenced by the child's age.
We found a range of HIV-1-specific CD8 T cell responses in both early and late treatment groups based on the level of virologic suppression. Total HIV-1-specific CD8 T cell responses for both virologically suppressed and viremic children receiving late treatment with HAART were more vigorous than those of their younger, early HAART-treated counterparts. However, in both the early and late HAART treatment groups, HIV-1-specific CD8 T cell responses persisted in the absence of plasma viremia at detectable levels.
The observed differences in the strength and breadth of the HIV-1-specific CD8 T cell response between younger and older children may reflect an age-dependent maturation of the immune system, and with it maturation of the HIV-1-specific CD8 T cell response. Exposure to viral antigens beyond the period of primary viremia might be required to more effectively shape the CD8 T cell response against a variety of HIV-1 epitopes. The strength of the HIV-1-specific CD8 T cell response observed for the older and coincidentally late HAART-treated patients could be due to the presence of an expanded memory CTL population. The expansive CD8 T cell response more typical of the older, late HAART-treated patients may prove vital in cases of viral mutation and/or drug failure. The maturation of an effective immune response to HIV-1 may be mitigated by the early initiation of HAART and the corresponding reduction of virus load. For primary HIV-1 infection in adults, the prognostic importance of the magnitude of spontaneous primary viremia reduction as an indicator for the effectiveness of the adaptive HIV-1-specific immune response has been established [1, 2] . For infants, containment of viremia with establishment of the virologic set point is a prolonged process that extends into early childhood. In most adults, a fully developed cellular immune response to HIV-1 is present by 3 months after primary infection, but effective antiretroviral interventions within the period of early primary infection reduce the magnitude of the HIV-1-specific CTL response and the HIV-1-specific antibody response [28] . Early HAART-treated adults are capable of CTL responses in magnitude and breadth comparable to responses seen in chronically HIV-1-infected persons [27] . In our study, the total CD8 T cell responses in the early HAART treatment group (analyzed on average у1 year after initiation of HAART) were not significantly different from the total CD8 T cell responses in the age-matched, non-HAART-treated control group.
In addition to the influence of the patient's age, differences in CD8 T cell responses between early and late HAART-treated pediatric patients could further be due to more effective priming of the HIV-1-specific CD8 T cell responses in patients treated early with HAART. Under these circumstances, a lower frequency of HIV-1-specific CD8 T cells might be required for effective containment of HIV-1 viremia, in particular within the group of infants with undetectable HIV-1 plasma RNA but with detectable CD8 T cells. Expanded CD8 T cell effectors might recognize more HIV-1 epitopes important for viral replication and generate more effective cytotoxicity or noncytolytic factors, which correlate with a more favorable outcome in infants [32] . HIV-1-specific CD4 T lymphocytes, which are protected from deletion during primary infection when effective antiretroviral therapy is initiated early, may be involved in priming a more effective initial HIV-1-specific CD8 T cell response. While early suppression of viral replication has so far been well tolerated by infected infants [25] , no outcome data are available for infants treated later. With initiation of effective antiretroviral therapy, the HIV-1-specific immune response diminishes and does not appear to be a major factor determining the success of the antiretroviral regimen as long as viral replication is effectively suppressed [21, 22, 24, 33] . Infants and children who are on effective antiretroviral medication would be in need of immunologic containment of HIV-1 only in cases of breakthrough viremia, for reduction of residual replication, or when discontinuation of the regimen may become necessary. Major differences exist between individual children in the virologic set point and magnitude and effectiveness of their HIV-1-specific immune response, determining disease progression and outcome [4, 5, 13, 16] . Without intervention, у20% of vertically infected infants will have rapid disease progression and face early demise. Early HIV-1-specific therapy is currently the most promising option for such children. Virologic and immunologic responses in children after early initiation of HAART show at least equally effective long-term containment of viral replication, total HIV-1-specific CD8 T cell responses equivalent to those seen in an age-matched non-HAARTtreated control group, and the potential benefit of conservation of critical immune function.
When continued or intermittent exposure to viral antigen is instrumental for long-term development and maintenance of a diverse HIV-1-specific CD8 T cell repertoire, differences in the total HIV-1-specific CD8 T cell response between the different virologic responder groups among the early HAART-treated children might become apparent as the children get older. Vaccine trials as intervention to increase HIV-1-specific CD8 T cell responses may be indicated for the HAART-treated, virologically suppressed patients, if the diminished strength and breadth of the HIV-1-specific CD8 T cell response persists later in life.
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